Pharma Journalist 7879 posts 0 comments

This week marks your last chance to save up to $350 on your ticket to 5th Genome Editing Therapeutics Summit (formerly known as CRISPR 2.0). With industry giants like Beam,…
Read More...

Inocras Inc. and Summit Pharmaceuticals International Corporation signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing…
Read More...

Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo…
Read More...

In a few weeks’ time, industry’s foremost drug developers will be convening at the 5th Genome Editing Therapeutics Summit* (December 3-5 | Boston, MA), the only industry meeting…
Read More...

GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T…
Read More...

Novartis announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia…
Read More...

Biogen Inc. and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and…
Read More...

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with…
Read More...

The 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Summit) this December will be your foremost drug development focused gene editing meeting, providing you with the…
Read More...